http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
손대원 한국수학교육학회 2014 뉴스레터 Vol.30 No.5
정육면체 전개도의 개수가 117~인 이유를 정사각형을 하나씩 추가해서 정사각형 6개가 붙어있는 357~의 헥사 미노를 찾고 정육면체 전개도가 되는 헥사미노 11개를 찾을 수 있다 전개도라는 단어처럼 정육면체의 모서리를 칼로 잘라서 펼치는 아이디어로 수형도를 그려서 정육면체의 전개도가 11개임을 구체적으로 알 수 있다.
손대원,김형관,김명아,송영욱,노정일,강이석,김호중,이상도,김영휘,윤호중,정남식,최재영,전재범,신진호 대한심장학회 2009 Korean Circulation Journal Vol.39 No.3
Background and Objectives: The purpose of this study was to investigate 1) the beneficial effect of bosentan treatment (125 mg twice daily) on exercise capacity and echocardiographic variables and 2) the profiles and frequency of adverse events in Korean patients with World Health Organization (WHO) class III or IV pulmonary artery hypertension (PAH). Subjects and Methods: Twelve patients who received bosentan treatment were investigated in an open label manner. One patient was excluded in the final analyses due to a prohibited concomitant medication. A 6-minute walk test and echocardiography were performed at baseline and after 12 weeks of treatment. Results: The administration of bosentan for 12 weeks resulted in a significant improvement in exercise capacity (measured with the 6-minute walking distance), WHO functional capacity, and in echocardiographic variables. Bosentan treatment was associated with a decrease in the maximal tricuspid regurgitation jet velocity {from 4.7 m/sec (95% confidence interval, 3.89-5.45) at baseline to 4.4 m/sec (95% confidence interval, 3.61- 5.1) at 12 weeks, p=0.03} and systolic pulmonary arterial pressure {from 105 mmHg (95% confidence interval, 74.4-135.6) at baseline to 93 mmHg (95% confidence interval, 66.3-120.1) at 12 weeks, p=0.04}. Treatment with bosentan at a dose of 125 mg twice a day was not associated with life-threatening side effects, although a higher incidence of elevated liver enzymes compared to previous studies was noted. Conclusion: Bosentan at a dose of 125 mg twice daily is considered a clinically optimal, safe dose and can be used as a valuable treatment option in Korean PAH patients with WHO functional capacity III or IV, though close monitoring of liver function is required.